Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 4/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.42 |
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31140652 | 0.83 | PRKCI (0.44) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL25237197 | 0.83 | PRKCI (0.44) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL1329786 | 0.77 | PRKCI (0.47) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL1328230 | 0.76 | PRKCI (0.51) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL1328009 | 0.76 | PRKCI (0.44) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL1328408 | 0.76 | ROCK1 (0.46) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL1328465 | 0.76 | PRKCI (0.44) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL857174 | 0.75 | JAK2 (0.53) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL1328069 | 0.75 | PRKCI (0.46) | PRKCIAXLAURKBJAK2JAK3 | |
| SCHEMBL78242 | 0.75 | LRRK2 (0.56) | PRKCIAXLAURKBJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111416154-B | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2021-08-06 | — | — | CN | claimed |
| CN-111416154-A | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2020-07-14 | — | — | CN | claimed |
| CN-111416154-B | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2021-08-06 | — | — | CN | disclosed |
| CN-111416154-A | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2020-07-14 | — | — | CN | disclosed |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | PRKCI 245/4885AXL 100/4885AURKB 768/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | PRKCI 276/4885AXL 470/4885AURKB 1197/4885 |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | PRKCI 46/4885AXL 383/4885AURKB 296/4885 |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | PRKCI 245/4885AXL 100/4885AURKB 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.